Milestone Scientific EPS Misses by $0.01 on Apr 1, 2026: Milestone Scientific missed EPS by $0.01 on Apr 1, 2026 and recorded revenue below estimates, highlighting execution risk in this micro-cap… 👈 Read full analysis #MilestoneScientific #EPSMiss #DentalDevices #SmallCapStocks #Investing
Milestone Scientific EPS Misses by $0.01 on Apr 1, 2026
Milestone Scientific missed EPS by $0.01 on Apr 1, 2026 and recorded revenue below estimates, highlighting execution risk in this micro-cap dental-device specialist.
dlvr.it
April 1, 2026 at 4:36 AM
Milestone Scientific EPS Misses by $0.01 on Apr 1, 2026: Milestone Scientific missed EPS by $0.01 on Apr 1, 2026 and recorded revenue below estimates, highlighting execution risk in this micro-cap… 👈 Read full analysis #MilestoneScientific #EPSMiss #DentalDevices #SmallCapStocks #Investing
Forian Q1 Misses EPS by $0.07, Revenue Tops Estimates: Forian's Q1 (Mar 31, 2026) showed an EPS miss of $0.07 while revenue topped estimates, creating a mixed signal for institutional investors. 👈 Read full analysis #Forian #EarningsReport #EPSMiss #RevenueGrowth #Investing
Forian Q1 Misses EPS by $0.07, Revenue Tops Estimates
Forian's Q1 (Mar 31, 2026) showed an EPS miss of $0.07 while revenue topped estimates, creating a mixed signal for institutional investors.
dlvr.it
March 31, 2026 at 5:11 AM
Forian Q1 Misses EPS by $0.07, Revenue Tops Estimates: Forian's Q1 (Mar 31, 2026) showed an EPS miss of $0.07 while revenue topped estimates, creating a mixed signal for institutional investors. 👈 Read full analysis #Forian #EarningsReport #EPSMiss #RevenueGrowth #Investing
Boston Omaha Q1 Results: EPS Misses, Revenue Tops: Boston Omaha (BOMN) reported an EPS shortfall of $0.19 on Mar 31, 2026 while revenue topped estimates, prompting scrutiny of margins and capital allocation. 👈 Read full analysis #BostonOmaha #Q1Results #EPSMiss #RevenueTops #InvestorInsights
Boston Omaha Q1 Results: EPS Misses, Revenue Tops
Boston Omaha (BOMN) reported an EPS shortfall of $0.19 on Mar 31, 2026 while revenue topped estimates, prompting scrutiny of margins and capital allocation.
dlvr.it
March 31, 2026 at 1:10 AM
Boston Omaha Q1 Results: EPS Misses, Revenue Tops: Boston Omaha (BOMN) reported an EPS shortfall of $0.19 on Mar 31, 2026 while revenue topped estimates, prompting scrutiny of margins and capital allocation. 👈 Read full analysis #BostonOmaha #Q1Results #EPSMiss #RevenueTops #InvestorInsights
TPI Composites Q1 EPS Misses by $1.86: TPI Composites reported an EPS miss of $1.86 on Mar 29, 2026 and revenue below estimates, prompting scrutiny of backlog, margins and liquidity. 👈 Read full analysis #TPICOMPOSITES #EarningsReport #EPSMiss #FinancialNews #StockMarket
TPI Composites Q1 EPS Misses by $1.86
TPI Composites reported an EPS miss of $1.86 on Mar 29, 2026 and revenue below estimates, prompting scrutiny of backlog, margins and liquidity.
dlvr.it
March 29, 2026 at 4:36 AM
TPI Composites Q1 EPS Misses by $1.86: TPI Composites reported an EPS miss of $1.86 on Mar 29, 2026 and revenue below estimates, prompting scrutiny of backlog, margins and liquidity. 👈 Read full analysis #TPICOMPOSITES #EarningsReport #EPSMiss #FinancialNews #StockMarket
Journey Medical Misses EPS by $0.50: Journey Medical missed EPS by $0.50 and reported revenue below estimates on Mar 26, 2026 (Investing.com); investors should review the company’s 8-K and guidance for line-item… 👈 Read full analysis #JourneyMedical #EPSMiss #Investing #PharmaNews #RevenueReported
Journey Medical Misses EPS by $0.50
Journey Medical missed EPS by $0.50 and reported revenue below estimates on Mar 26, 2026 (Investing.com); investors should review the company’s 8-K and guidance for line-item detail.
dlvr.it
March 26, 2026 at 1:27 AM
Journey Medical Misses EPS by $0.50: Journey Medical missed EPS by $0.50 and reported revenue below estimates on Mar 26, 2026 (Investing.com); investors should review the company’s 8-K and guidance for line-item… 👈 Read full analysis #JourneyMedical #EPSMiss #Investing #PharmaNews #RevenueReported